Cover page; Halftitle page; Title page; Copyright page; Contents; Acknowledgments; chapter one Introduction: The Psychedelic Renaissance Continues; PART 1 Psychiatry; chapter two Psychedelics and Psychiatry: A New Treatment Model for the 21st Century; chapter three Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA); chapter four Psilocybin Therapy for Major Depressive Disorder; chapter five Ketamine Therapy for Treatment-Resistant Depression; chapter six Evidence for the Therapeutic Effects of Ayahuasca; PART 2 Substance Abuse
Chapter seven Psilocybin for the Treatment of Substance Use Disorderschapter eight Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction; chapter nine Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders*; PART 3 Medical Hypotheses; chapter ten Effects of Psychedelics on Inflammation and Immunity; chapter eleven The Protective Role ofDimethyltryptamine against Ischemia-Reperfusion Injury; chapter twelve Psychedelic Treatment of Disruptive Personality Patterns; PART 4 Treatment and Training
Chapter thirteen Guidelines in Applying Psychedelic Therapieschapter fourteen Training Psychedelic Therapists; PART 5 Societal Engagement with Psychedelics; chapter fifteen Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- andPsychedelic-Related Problems at a Transformational Festival; chapter sixteen Microdosing Psychedelics; chapter seventeen Bringing Psyched elics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA; About the Editors and Contributors; Index
